Good news for all those with weight problems and diabetes: the Italian Medicines Agency (AIFA) has authorized the prescription marketing of tirzepatide, a drug indicated for the treatment of obesity , and type 2 diabetes. In clinical trials, treatment with Lilly's drug resulted in significant weight reduction in both adult patients with obesity and those with overweight with at least one related comorbidity, as well as demonstrated important results in glycemic control in adults with type 2 diabetes. "Despite the strides made in recent years, obesity remains a very complex condition for professionals and health systems to address, with important cultural and care deficiencies," says Rocco Barazzoni, President of the Italian Obesity Society (SIO). “Today we are finally entering a new phase in the treatment of obesity with a new pharmacological paradigm that will allow us not only to provide answers to hitherto largely unmet care needs, restoring time and quality of life to patients, but also to prevent in the long term the many associated pathologies and reduce their dramatic impact today”.